Company Overview and News
Investors are always looking for stocks that are poised to beat at earnings season and Citizens Financial Group, Inc. (CFG - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Citizens Financial Group is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
CFG CFIN MBWM CIWV CTRL UNH
The market expects Citizens Financial Group (CFG - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
CFG CFIN CIWV
JPMorgan (JPM - Free Report) recently announced that it plans to expand in New England region. This is part of the company’s initiative to expand into 15-20 new markets, which was unveiled in January 2018. The bank will be opening at least 60 retail branches, 130 ATMs and hire nearly 350 new employees in the region by the end of 2023. Specifically, JPMorgan intends to enter Greater Boston by opening 50 retail banking branches, while around 8-10 are likely to be located in Rhode Island.
BAC CFG CFIN BAC TNTTF CIWV TD TD
JPMorgan (JPM - Free Report) recently announced that seeks to expand in Philadelphia and the Delaware Valley. This is part of its plan to expand into 15-20 new markets. The bank will be opening 50 retail branches and hire around 300 new employees in the region by the end of 2023. Further, JPMorgan will invest $3 billion toward mortgage and small business lending in the area and $5 million to help revitalize Philadelphia's Kensington Avenue neighborhood over the next five years.
WFC WFCNP CFG CFIN CIWV
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Citizens Financial Group (CFG - Free Report) , which belongs to the Zacks Financial - Savings and Loan industry, could be a great candidate to consider.
CFG CFIN CIWV
The restructuring process that begun with an aim to “reduce or eliminate operating and regulatory burdens and inefficiencies” and lower operating expenses is finally coming to an end. Zions Bancorporation (ZION - Free Report) has received regulatory approval for the removal of the “systemically important financial institution" (SIFI) label. The Financial Stability Oversight Council (FSOC) voted 9 to 0 to remove Zions from SIFI list, thereby, freeing the bank from stricter regulatory oversight by the Federal Reserve.
BBT ZIONW CFG CFIN ZBK ZION CIWV ZIONZ
U.S. equities are suffering another bout of weakness on Wednesday, falling into negative territory after a big intraday reversal pushed the Dow Jones Industrial Average back below the 26,000 level. The catalyst, as you may have guessed, was more fears on the trade front. Reports are crossing that adding Canada to the recently penned bilateral trade deal between the United States and Mexico could be more difficult than previously believed.
BPFH MBFI CHFN CFG USB CFIN BPFHW STI CIWV STI-A BPFHP STL FITB CSFL SBT
NEW YORK, Sept. 07, 2018 (GLOBE NEWSWIRE) -- Mizuho Americas today announced the hiring of four professionals in its US Corporate and Investment Banking unit: Jeffrey Tuckel, Robert Minikes, Joseph Flores and Stephen Robb. Tuckel, Minikes and Flores will help drive and grow Mizuho’s Financial Sponsors business and will be based in Los Angeles reporting to Keith A. Wargo, Co-Head of Corporate and Investment Banking.
CFG CFIN MZHOF CIWV 8411 MFG
2018-09-03 seekingalpha - 10
This article is part of a series that provides an ongoing analysis of the changes made to David Tepper’s 13F portfolio on a quarterly basis. It is based on Appaloosa Management’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking David Tepper’s Appaloosa Management Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018.
PCG LRCX SYMC KMT CQP CNC VST XOP KEY NRGEO CFIN WPZ BSX CIWV HCA SYK AABA AMAT WMB SUM BTUUQ VNTR BAC TMUSP LNG TMUS OC NRG ALL BABA ETP CZR GOOGL WMIH TERP WFCNP MGM FB PAH AY TMO WDC NVDA GOOG BAC HUN AGN UBS WFC WMIHP GJT XPO CFG BTU ALLY MU VSTE URI DG ULSGF
Stocks were up again on Wednesday, but just barely … another day the bulls were hesitant to add to the recent rally. Politics played its role in the pause, but odds are good that the sheer weight of all the recent bullishness is what’s really holding the market back. The headlines are just an excuse.
CFG CFIN ZNGA TGT CIWV ADI GGP DIS
2018-08-03 zacks - 1
The shipping industry is responsible for transporting the majority of goods involved in world trade and is rightfully considered as the life line of the global economy. Since the beginning of 2017, the shipping industry has been witnessing rapid growth. The momentum is expected to continue in 2018. This is primarily due to higher demand for commodities from the emerging markets of China and India as well as from Europe.
CFIN SBLKL KNOP CY CIWV DSXN DSX PF SBLK NMM
Motorola Solutions, Inc. (MSI - Free Report) reported strong second-quarter 2018 results on the back of healthy growth across all geographic regions. GAAP earnings for the reported quarter were $180 million or $1.05 per share compared with $131 million or 78 cents per share in the year-earlier quarter. The year-over-year improvement was primarily attributable to top-line growth. Excluding non-recurring items, non-GAAP earnings for the reported quarter were $1.
CFIN MSI CMTL CY CIWV PF QCOM CLFD
Cooper Tire & Rubber Company (CTB - Free Report) is set to report second-quarter 2018 results, before the market opens on Aug 6. In the last-reported quarter, this tire manufacturer delivered an earnings miss of 73.3%. In the trailing four quarters, it missed estimates twice while beating in the remaining two, with an average negative earnings surprise of 9.8%. Cooper Tire has an expected long-term growth rate of 4%.
CFIN CY CIWV PPL GPS PF AAP
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET